Analysts Issue Forecasts for KYTX FY2029 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Stock analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for Kyverna Therapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($4.19) per share for the year. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.01. The firm had revenue of $0.01 million for the quarter.

A number of other equities research analysts have also issued reports on KYTX. UBS Group initiated coverage on shares of Kyverna Therapeutics in a report on Thursday, October 10th. They set a “buy” rating and a $13.00 target price on the stock. HC Wainwright reduced their price objective on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. Finally, Wells Fargo & Company lowered their target price on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, November 15th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.71.

Kyverna Therapeutics Price Performance

NASDAQ KYTX opened at $3.11 on Friday. The firm has a 50 day simple moving average of $3.96 and a 200-day simple moving average of $5.47. Kyverna Therapeutics has a one year low of $3.02 and a one year high of $35.06.

Institutional Trading of Kyverna Therapeutics

A number of institutional investors have recently bought and sold shares of the business. FMR LLC purchased a new stake in shares of Kyverna Therapeutics during the 3rd quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new position in Kyverna Therapeutics in the 4th quarter valued at about $34,000. Creative Planning purchased a new stake in shares of Kyverna Therapeutics during the third quarter worth approximately $54,000. Jacobs Levy Equity Management Inc. purchased a new position in Kyverna Therapeutics during the 3rd quarter worth $97,000. Finally, Rhumbline Advisers lifted its stake in shares of Kyverna Therapeutics by 31.1% in the 4th quarter. Rhumbline Advisers now owns 25,920 shares of the company’s stock worth $97,000 after acquiring an additional 6,153 shares during the period. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.